Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205
06 janv. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
Response to pre-IND briefing package supports pathway to initiating a Phase 1 clinical study in 2022 BOTHELL, Wash., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP)...